ANTXHealthcareMicro-Cap
AN2 Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for AN2 Therapeutics, Inc. (ANTX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are ANTX insiders buying or selling?
AN2 Therapeutics, Inc. insiders reported 20 open-market buys ($53.8M) and 43 sells ($18.7M) across 63 Form 4 filings — a net buying position of $35.0M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 10, 2026)
Total Form 4 filings
63
SEC EDGAR
Insider filers
14
Insider buys (20)
$53.8M
Insider sells (43)
$18.7M
Insider sentiment
Net buyingNet insider flow of $35.0M in net buying.
Recent ANTX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 10, 2026 | Joshua M Eizen | Chief Operating Officer and Chief Legal Officer | Sale | 5.9K | $4.17 | $24.8K |
| Jun 2, 2026 | Sarah Joanne Williams | Principal Accounting Officer | Sale | 265 | $4.43 | $1.2K |
| Mar 5, 2026 | Sarah Joanne Williams | Principal Accounting Officer | Sale | 327 | $1.06 | $346.62 |
| Jan 8, 2026 | Lucy Day | Chief Financial Officer | Sale | 8.8K | $1.01 | $8.9K |
| Jan 8, 2026 | Stephen David Prior | Chief Strategy Officer | Sale | 6.5K | $1.01 | $6.5K |
| Jan 8, 2026 | Sanjay Chanda | Chief Development Officer | Sale | 9.3K | $1.01 | $9.3K |
| Jan 8, 2026 | Joshua M Eizen | Chief Operating Officer and Chief Legal Officer | Sale | 24.9K | $1.00 | $25.0K |
| Nov 6, 2025 | Joshua M Eizen | Chief Operating Officer and Chief Legal Officer | Sale | 2.8K | $1.14 | $3.2K |
| Nov 6, 2025 | Stephen David Prior | Chief Strategy Officer | Sale | 765 | $1.14 | $872.1 |
| Jun 16, 2025 | Braden Michael Leonard | 10% Owner | Sale | 200.0K | $1.09 | $218.0K |
| Jun 3, 2025 | Easom Eric | Chief Executive Officer | Purchase | 10.0K | $1.07 | $10.7K |
| May 30, 2025 | Braden Michael Leonard | 10% Owner | Sale | 2.5M | $1.13 | $2.9M |
| May 29, 2025 | Margaret M Fitzpatrick | Director | Purchase | 8.6K | $1.18 | $10.1K |
| Jan 8, 2025 | Lucy Day | Chief Financial Officer | Sale | 3.0K | $1.34 | $4.0K |
| Jan 8, 2025 | Sanjay Chanda | Chief Development Officer | Sale | 3.0K | $1.34 | $4.0K |
| Jan 8, 2025 | Stephen David Prior | Chief Strategy Officer | Sale | 2.0K | $1.34 | $2.7K |
| Jan 8, 2025 | Joshua M Eizen | Chief Operating Officer and Chief Legal Officer | Sale | 9.7K | $1.34 | $13.0K |
| Dec 11, 2024 | Robin Shane Readnour | Director | Purchase | 60.0K | $1.45 | $86.7K |
| Nov 28, 2024 | Robin Shane Readnour | Director | Purchase | 75.0K | $1.41 | $105.7K |
| Nov 27, 2024 | Joseph S Zakrzewski | Director | Purchase | 2.0K | $1.40 | $2.8K |
| Nov 21, 2024 | Robin Shane Readnour | Director | Purchase | 200.0K | $1.07 | $213.1K |
| Nov 20, 2024 | Joseph S Zakrzewski | Director | Purchase | 25.0K | $1.00 | $25.0K |
| Nov 19, 2024 | Easom Eric | Chief Executive Officer | Purchase | 50.0K | $1.00 | $50.0K |
| Aug 15, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 1.5M | $1.04 | $1.6M |
| Aug 13, 2024 | Peter Kolchinsky | 10% Owner | Sale | 3.5M | $1.08 | $3.8M |
Showing the 25 most recent of 63 Form 4 filings for AN2 Therapeutics, Inc..
Most active ANTX insiders
- Easom Eric11 filings
- Adjuvant Global Health Technology Fund L.P.9 filings
- Kabeer Aziz8 filings
- Peter Kolchinsky7 filings
- Robin Shane Readnour6 filings
Ask anything about ANTX insider activity
Use Trabud's AI agent to query AN2 Therapeutics, Inc.'s Form 4 history in plain English — "Show me ANTX CEO purchases this year" or compare it against any other ticker.
Open the AI agentANTX insider trading FAQ
Are AN2 Therapeutics, Inc. insiders buying or selling?
Across 63 SEC Form 4 filings, AN2 Therapeutics, Inc. (ANTX) insiders reported 20 open-market purchases totaling $53.8M and 43 sales totaling $18.7M. That is a net buying position of $35.0M.
How many insiders trade ANTX stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for AN2 Therapeutics, Inc.. The most recent filing was accepted on Jul 10, 2026.
Where does Trabud get ANTX insider trading data?
All ANTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.